NEUROMOLECULAR MEDICINE, published by HUMANA PRESS INC, is a prestigious peer-reviewed journal dedicated to advancing the fields of cellular and molecular neuroscience, molecular medicine, and neurology. With an ISSN of 1535-1084 and an E-ISSN of 1559-1174, the journal boasts a significant presence in academic research since its inception in 2002 and continues to publish cutting-edge studies through 2024. Ranked in the Q2 category for 2023 in various disciplines, including Neuroscience and Molecular Medicine, it holds impressive positions in Scopus rankings, including 41st out of 192 in Neuroscience and Neurology. Although not an open access journal, NEUROMOLECULAR MEDICINE remains invaluable for researchers, professionals, and students seeking to explore the intricate relationships between molecular mechanisms and neurological functions, thereby contributing to the scientific understanding of nervous system diseases and therapeutic innovations.

NATURE NEUROSCIENCE is a premier journal published by NATURE PORTFOLIO, focusing on cutting-edge research in the field of neuroscience. With an esteemed impact factor that reflects its significance in the academic community, this journal occupies an exceptional place in the 2023 Q1 category for neuroscience (miscellaneous) and boasts a leading Scopus rank of #1 out of 113 in general neuroscience, placing it within the top 1st percentile. Since its inception in 1998, NATURE NEUROSCIENCE has consistently delivered high-quality, peer-reviewed articles that contribute to our understanding of the nervous system, driving innovation and scholarship across disciplines. Although it does not offer open access, the journal remains a vital resource for researchers, professionals, and students seeking to stay at the forefront of neuroscientific discovery and discussion. Its editorial commitment to excellence ensures that it continually shapes the trajectory of neuroscience research well into 2024 and beyond, making it an indispensable asset for anyone passionate about the brain and its complexities.

CRITICAL REVIEWS IN IMMUNOLOGY, published by BEGELL HOUSE INC, is an essential journal in the field of immunology that has been contributing to the scientific discourse since 1980. With its ISSN 1040-8401 and E-ISSN 2162-6472, this journal provides a platform for critical analysis and comprehensive reviews that deepen understanding of immune responses and their implications in health and disease. Although currently categorized in the Q4 quartile for Immunology and Q3 for Immunology and Allergy, the journal's quality research and scholarly contributions are crucial for advancing knowledge within its fields—encompassing various aspects of innate and adaptive immunity. Researchers and professionals in immunology will find invaluable insights, aiding them in their quest for innovation and excellence, as the journal aims to foster interdisciplinary collaboration. While it does not operate on an open-access model, CRITICAL REVIEWS IN IMMUNOLOGY remains a significant resource for those dedicated to pushing the boundaries of immunology, with annual publications expected to last well into 2024 and beyond.

Journal of Neuroinflammation is a premier open-access journal published by BMC that has been at the forefront of research in the field since its inception in 2004. With a strong focus on the intricate interplay between the nervous system and immune responses, this journal aims to create a forum for the dissemination of high-quality research that informs our understanding of neuroinflammation and its implications in neurological disorders. Positioned in the top quartile across multiple categories including Cellular and Molecular Neuroscience, Immunology, and Neurology, the journal ranks impressively within the Scopus database, ensuring visibility to the global research community. The Journal of Neuroinflammation provides a vital platform for researchers and professionals to share groundbreaking findings, methodologies, and reviews that advance science and foster collaboration. With its commitment to open access, the journal ensures that its content is accessible to a broad audience, enhancing the dissemination of knowledge in this critical field of study.

Neurology-Neuroimmunology & Neuroinflammation, published by LIPPINCOTT WILLIAMS & WILKINS, stands at the forefront of research in the rapidly evolving fields of neurology and neuroimmunology. Since its inception in 2014, this prestigious journal has embraced an Open Access model, ensuring that groundbreaking findings are readily available to researchers, clinicians, and students worldwide. Covering a broad spectrum of topics related to neuroinflammation, the journal has gained a remarkable reputation, attaining a Q1 ranking in both Neurology and Neurology (clinical) as of 2023, and ranking #6 out of 192 in the neuroscience category on Scopus. The journal's commitment to high-quality research aims to facilitate the understanding of neurological disorders, promote innovative therapies, and inspire collaboration among professionals. Addressing critical issues at the intersection of neurology, immunology, and clinical practice, Neurology-Neuroimmunology & Neuroinflammation is an essential platform for the dissemination of knowledge and the advancement of this vital field.

International Immunopharmacology, published by Elsevier, stands as a prominent journal within the disciplines of immunology and pharmacology. With an ISSN of 1567-5769 and an E-ISSN of 1878-1705, this esteemed journal is based in the Netherlands and features a robust commitment to disseminating high-quality research from its inception in 2001 through 2024. The journal has achieved impressive rankings, securing a Q1 category in Pharmacology and Q2 in both Immunology and Immunology and Allergy as of 2023. With its strategic focus on bridging the gap between immunology and pharmacological applications, International Immunopharmacology attracts a diverse readership, including researchers, healthcare professionals, and students interested in the latest advancements in therapeutic agents and immune system modulation. Furthermore, it offers an open access option, enhancing the accessibility and reach of its invaluable content. As a pivotal resource in the field, this journal not only facilitates the exchange of innovative ideas but also fosters a deeper understanding of the complexities of immunopharmacology in today’s research landscape.

ACTA NEUROPATHOLOGICA, published by Springer, is a leading journal in the fields of cellular and molecular neuroscience, clinical neurology, and pathology, recognized for its exceptional quality and impactful research. With an impressive impact factor and currently ranked in the Q1 tier across multiple categories in 2023, this journal serves as a premier platform for the dissemination of groundbreaking findings in neuropathology. The journal's robust Scopus rankings highlight its influence, standing at #2 in Pathology and Forensic Medicine and #5 in Clinical Neurology. Since its inception in 1961, ACTA NEUROPATHOLOGICA has provided crucial insights into neurological diseases and disorders, contributing significantly to the advancement of medical science. Aimed at researchers, practitioners, and students alike, this journal fosters a deeper understanding of neurological conditions and encourages innovative approaches within the field. It is essential reading for anyone dedicated to unraveling the complexities of the nervous system.

The Lancet Neurology is a premier academic journal published by Elsevier Science Inc, specializing in the field of neurology. With a robust impact factor that signifies its authoritative presence, it consistently ranks in the Q1 category for clinical neurology according to the 2023 standards, positioning itself as the leading journal in its domain, ranking #1 out of 400 in Scopus' neurology rankings and placing in the 99th percentile. Since its establishment in 2002, it has provided a vital platform for disseminating innovative research and clinical advances related to neurological disorders. The journal’s precise focus includes cutting-edge studies on neurodegenerative diseases, stroke, epilepsy, and neuroimaging, which are essential for advancing clinical practice and improving patient outcomes. While it does not offer open access, readers can find high-impact research published monthly, making it indispensable for practitioners, researchers, and students eager to stay at the forefront of neurological science.

Cellular & Molecular Immunology is a prestigious peer-reviewed journal published by the CHIN SOCIETY IMMUNOLOGY. As a leading journal in the fields of immunology and infectious diseases, it proudly holds a Q1 designation across multiple categories, including Immunology, Allergy, and Medicine (Miscellaneous), reflecting its commitment to excellence and impactful research. With an ISSN of 1672-7681 and an E-ISSN of 2042-0226, the journal has been essential reading since its inception in 2004, continuously gathering insights from cutting-edge studies. It ranks impressively within Scopus, with positions in the 7th, 8th, and 9th percentile in relevant categories, establishing it as a cornerstone for researchers, clinicians, and students alike. The journal offers an extensive range of original research articles, reviews, and clinical studies, ensuring that readers stay at the forefront of immunological discovery. Whether you are interested in basic immunology, infectious diseases, or evolving therapies, Cellular & Molecular Immunology serves as an invaluable resource for advancing your knowledge and engagement in this dynamic field.

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.